top of page

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Updated: 4 days ago


Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- At YD Bio Limited (“YD Bio,” Nasdaq: YDES), we are dedicated to advancing DNA methylation-based cancer detection and next-generation diagnostic innovations. As part of this mission, we are pleased to share an update on our U.S. expansion of the OkaiDx™ platform for post-treatment breast cancer monitoring, along with our continued progress in extending OkaiDx™ to pancreatic and colorectal cancer detection and our newest clinical findings in early pancreatic cancer detection.


Building on our previously announced research-use-only OkaiDx breast cancer monitoring assay offered through our affiliate EG BioMed’s CAP/CLIA-certified laboratory, we have expanded clinical service availability for the OkaiDx platform across the United States. Through EG BioMed’s accredited laboratory in Washington, we now provide blood-based testing services for pancreatic and colorectal cancer detection in 44 states. This growing access is supported by a nationwide telehealth physician network that enables virtual consultations, test authorization, and patient support, together with an at-home blood collection partner to simplify logistics for both patients and research collaborators.


To strengthen our reach in primary care and women’s health settings, we have also entered into new memorandums of understanding with multiple medical groups in the U.S. These collaborations integrate OkaiDx testing into daily clinical workflows and help broaden access for individuals who may benefit from proactive detection and ongoing monitoring.


We would also like to highlight updated data from the ongoing study conducted by our affiliate, EG BioMed US Inc., on the OkaiDx Detect Pancreatic Cancer Test, carried out under Taipei Medical University-JIRB approval (IRB ID: N202105091). In a study of 100 PDAC patients and 500 healthy controls, the assay demonstrated:


  • 93.8% sensitivity for early-stage (stage I–II) pancreatic ductal adenocarcinoma (PDAC)

  • >99.0% sensitivity for late-stage PDAC

  • 97.3% specificity in healthy individuals

  • 97.7% overall accuracy


The OkaiDx Detect Pancreatic Cancer test has not been cleared or approved by the U.S. Food and Drug Administration, results are from an independently conducted EG BioMed study and remain under validation. About YD Bio Limited

YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, YD Bio’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on YD Bio’s current expectations and projections about future events that YD Bio believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. YD Bio undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although YD Bio believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and YD Bio cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in YD Bio’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

YD Bio Limited Investor Relations


WFS Investor Relations Inc.

Phone: +1 628 283 9214



Selected Media Coverage

bottom of page